The user started using 0.1% finasteride and 5% minoxidil twice daily and experienced an itchy scalp. Suggestions include checking for allergies, dry scalp, or seborrheic dermatitis.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
Minoxidil is causing severe scalp irritation, including itchiness and dryness, for the user. Alternatives suggested include anti-fungal treatments, propylene-glycol-free formulations, and possibly oral minoxidil.
Winlevi is being considered for hair loss by someone who wants to avoid systemic hormonal changes. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.
A user allergic to propylene glycol seeks alternatives for a DIY topical finasteride solution, considering glycerin or glycerol-based vehicles. Another user suggests a recipe using propanediol, DMSO, MCT oil, and peppermint oil, incorporating minoxidil, dutasteride, and finasteride.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
The conversation discusses microneedling for hair loss, with one user trying 0.3mm daily without feeling pain and questioning its effectiveness. Another user suggests that 0.3mm is too shallow and recommends 0.5mm twice a week or 0.75mm once a week for hair growth.
The user experienced redness and itching from using 5% minoxidil and is considering trying a lower dose or alternative treatments like 2% minoxidil, mesotherapy, PRP, or rosemary oil. They are seeking advice on managing side effects and exploring other options for hair stimulation.
RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
The user has been using finasteride for four years and topical minoxidil with microneedling for a year but has not seen significant results in slowing hair loss. They are considering trying dutasteride despite concerns about its intensity, and others suggest trying oral minoxidil or combining treatments for better results.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
A user is comparing the effectiveness and ingredients of name-brand hair fibers (Nanogen) versus cheaper generic options found on eBay. They are concerned about the presence of sodium chloride in the generic product and seek opinions on whether there is a significant difference in quality.
A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.
A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.
The efficacy of low doses of finasteride to reduce scalp DHT, and whether studies showing a 61% reduction are reflected in actual results. Replies discussed hair growth as an unintended consequence of minoxidil and finasteride use, as well as self-selective bias, potential side effects, and that studies measure effectiveness by hair count changes rather than DHT inhibition.
The conversation discusses the effectiveness and potential side effects of using a minoxidil, finasteride, and biotin combination pill for hair loss, comparing half-dose (0.55mg Fin, 2.5mg Min, 0.5mg Biotin) to full-dose (1.1mg Fin, 5mg Min, 1mg Biotin). The user is considering whether to increase to a full dose after starting with a half dose.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.
The conversation discusses the effectiveness of finasteride and dutasteride for hair loss, with some users finding no improvement and experiencing side effects. It also mentions the use of RU58841 and topical minoxidil, highlighting that hair sensitivity to DHT varies among individuals.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.
The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.